bluebird bio, Inc. (NASDAQ:BLUE) Director Nick Leschly sold 2,369 shares of bluebird bio stock in a transaction that occurred on Monday, January 10th. The stock was sold at an average price of $9.40, for a total transaction of $22,268.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ:BLUE opened at $8.73 on Friday. bluebird bio, Inc. has a 52-week low of $8.12 and a 52-week high of $52.80. The firm has a fifty day moving average of $10.34 and a 200 day moving average of $17.94.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Friday, November 5th. The biotechnology company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.65) by ($0.51). bluebird bio had a negative return on equity of 76.93% and a negative net margin of 1,610.78%. The company had revenue of $22.70 million during the quarter, compared to analysts’ expectations of $39.07 million. During the same quarter last year, the firm posted ($2.94) earnings per share. The firm’s revenue was up 17.6% on a year-over-year basis. Sell-side analysts predict that bluebird bio, Inc. will post -11.38 EPS for the current year.
A number of large investors have recently made changes to their positions in BLUE. Berman Capital Advisors LLC grew its position in bluebird bio by 3,217.0% in the third quarter. Berman Capital Advisors LLC now owns 1,758 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 1,705 shares in the last quarter. Lazard Asset Management LLC grew its position in bluebird bio by 4,861.3% in the second quarter. Lazard Asset Management LLC now owns 3,076 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 3,014 shares in the last quarter. Point72 Hong Kong Ltd grew its position in bluebird bio by 130.5% in the third quarter. Point72 Hong Kong Ltd now owns 6,474 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 3,665 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in bluebird bio in the second quarter worth $169,000. Finally, AGF Investments Inc. bought a new stake in bluebird bio in the third quarter worth $199,000. Institutional investors own 73.59% of the company’s stock.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
Recommended Story: What is a Buy-Side Analyst?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.